Together, these findings highlight that S100 proteins exhibit subtype- and stage-specific expression profiles in bladder cancer, which may serve as molecular correlates of tumor aggressiveness and potential biomarkers for patient stratification and therapeutic guidance. This evidence concerns the gene S100A1 and urinary bladder cancer.